Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib plus docetaxel and prednisone in metastatic castrate resistant prostate cancer
NCT01683994Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2012
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in prostate cancer (PCa), sponsored by National Cancer Institute. Started Sep 2012; status: completed.
02
Drugs
cabozantinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01683994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01683994.